Abstract 70P
Background
PD-1 blockade combined with chemotherapy has become the standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without oncogenic drivers. Oncogenic-driven advanced NSCLC showed limited response to PD-1 blockade monotherapy or chemotherapy alone. Whether NSCLC patients with oncogenic drivers showed response to PD-1 blockade plus chemotherapy remains undetermined.
Methods
329 patients with at least one oncogenic driver alteration NSCLC receiving PD-1 plus chemotherapy or each monotherapy were retrospectively identified. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were used to evaluate the therapeutic outcomes differences among patients with different oncogenic drivers.
Results
Totally, 176 patients received PD-1 blockade plus chemotherapy, 60 patients received PD-1 blockade monotherapy and 93 patients received chemotherapy alone were included. Oncogenic drivers including KRAS (31.0%), EGFR (30.4%), HER2 (14.6%), BRAF (10.3%), RET (7.0%) and other mutations (6.7%) were identified. Compared with PD-1 and chemo mono-treatment, patients with oncogenic drivers received PD-1 blockade plus chemotherapy showed significantly better objective response rate (48% vs 22% and 26%; P < 0.001), progression-free survival (median 9.5 vs 3.8 and 5.6 months; P < 0.001) and overall survival (median 25.3 vs 16.8 and 17.0 months; P < 0.001). Multivariate cox regression analysis revealed that PD-1 blockade plus chemotherapy showed dramatically improved benefits both in PFS and OS.
Conclusions
PD-1 blockade plus chemotherapy showed superior efficacy than PD-1 blockade monotherapy or chemotherapy alone in patients with oncogenic-driven advanced NSCLC, particularly in KRAS, EGFR and BRAF subgroup, indicating that PD-1 blockade plus chemotherapy could be considered as optional treatments when these patients without available targeted therapy.
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by grants from the National Natural Science Foundation of China (Nos.82102859, 82172869, 82141101, 82272875 and 12126605).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract